NKTR-214: Harnessing the IL-2 Pathway in Combination Immunotherapies
PharmaTalkRadio6 Mar 2020

NKTR-214: Harnessing the IL-2 Pathway in Combination Immunotherapies

In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Willem Overwijk, Nektar Therapeutics discusses Bempegaldesleukin (NKTR-214): harnessing the IL-2 pathway in combination immunotherapies. Topics include: Bempegaldesleukin: Structure and function of an engineered IL-2 cytokine prodrug providing sustained IL-2Rβγ-biased signalingPreclinical PK, PD, MOA and combination with PD-1 checkpoint inhibitionClinical PK, PD, clinical response data and biomarkers in patients with melanoma and bladder cancerCombinations under investigation To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(461)

Populært innen Vitenskap

fastlegen
tingenes-tilstand
rekommandert
jss
sinnsyn
liberal-halvtime
forskningno
tomprat-med-gunnar-tjomlid
fjellsportpodden
rss-overskuddsliv
villmarksliv
dekodet-2
rss-paradigmepodden
rss-inn-til-kjernen-med-sunniva-rose
rss-zahid-ali-hjelper-deg
kvinnehelsepodden
rss-rekommandert
hva-er-greia-med
nevropodden
aldring-og-helse-podden